

March 14, 2023

**CURRICULUM VITAE  
GEORGE PALMER BAYLISS, M.D.**

Business Address: Brown Medicine  
Division of Kidney Diseases and Hypertension  
375 Wampanoag Trail, Suite 402  
East Providence, RI 02915  
Business Telephone: 401-649-4063  
Business Fax: 401-649-4061  
E-mail Address: [george.bayliss@brownphysicians.org](mailto:george.bayliss@brownphysicians.org)

Business Address: Kidney Transplant Clinic  
APC9, Rhode Island Hospital  
593 Eddy Street  
Providence, RI 02903  
Business Telephone: 401-444-3284  
Business Fax: 401-444-3283  
E-mail Address: [gbayliss@lifespan.org](mailto:gbayliss@lifespan.org) (preferred)

**EDUCATION**

Undergraduate: Harvard University, AB, Slavic Languages & Literature, 1982. Magna Cum Laude  
Graduate: Columbia University School of International & Public Affairs, MA, International Affairs, 1986  
Medical School: Brown Medical School, MD, 2003  
Other Advanced Study:  
Columbia University Harriman Institute for the Advanced Study of the Soviet Union, Certificate, 1991  
Columbia University School of General Studies, Post-baccalaureate Premedical Studies, Certificate, 2000

**POSTGRADUATE TRAINING**

Internship: Rhode Island & the Miriam Hospitals, Brown Medical School, Internal Medicine 2003-2004  
Residency: Rhode Island & the Miriam Hospitals, Brown Medical School, Internal Medicine 2004-2006

Fellowship: Beth-Israel Deaconess Medical Center, Harvard Medical School, Nephrology, 2006-2008

POSTGRADUATE HONORS AND AWARDS

Scaife Family Foundation Scholarship, Rutgers School of Alcohol and Drug Studies, 2002

The Harvey P Lesselbaum Memorial Award, presented to a Senior Medical Resident for Professional Excellence and Inspirational Teaching, Brown Medical School, 2006

George Altman, MD, and Harriet Altman Nephrology Travel Award, Beth-Israel Deaconess Medical Center, Harvard, 2007

Certificate of Recognition for Exemplary Teaching, Alpert Medical School, Brown, 2009

Certificate of Recognition for Exemplary Teaching, Alpert Medical School, Brown, 2010

Dean's Award for Excellence in Teaching, Alpert Medical School, Brown, 2010

Certificate of Recognition for Exemplary Teaching, Alpert Medical School, Brown, 2011

Fellow, National Kidney Foundation, 2011

Dean's Award for Excellence in Teaching, Alpert Medical School, Brown, 2012

Beckwith Family Award for Outstanding Teaching, Alpert Medical School, Brown, 2013

Fellow of the American College of Physicians, 2014

Certificate of Recognition for Exemplary Teaching, Alpert Medical School, Brown, 2014

Alpha Omega Alpha, Alpert Medical School, Brown, 2015

Most Flexible Award, Internal Medicine Clerkship, Alpert Medical School, Brown, 2016

Dean's Excellence in Teaching Award, Alpert Medical School, Brown, 2017

Fellow of the American Society of Nephrology, 2018

Dean's Excellence in Teaching Award, Alpert Medical School, Brown, 2018

Named as a "Positive champion of the learning environment," Alpert Medical School, Brown, 2018

Certificate of Recognition for Exemplary Teaching, Alpert Medical School, Brown, 2019

Dean's Excellence in Teaching Award, Alpert Medical School, Brown, 2020

Named "Elite Reviewer" by the Journal of the American College of Cardiology, 2022

## PROFESSIONAL LICENSES

Massachusetts State Medical License 234263, October 2007-present

Rhode Island State Medical License MD12642, May 2008-present

## BOARD CERTIFICATION

American Board of Internal Medicine, Diplomate in Internal Medicine, 2006; recertified 2016

American Board of Internal Medicine, Diplomate in Nephrology, 2009; recertified in 2019

## ACADEMIC APPOINTMENTS

Clinical Fellow in Nephrology, Harvard Medical School, 2006-2008

Assistant Professor of Medicine, Alpert Medical School, Brown University, 08/2008-06/2016

Associate Professor of Medicine, Alpert Medical School, Brown University, 07/2016-present

Adjunct Professor of Nursing, College of Nursing, University of Rhode Island, 10/2020-present

## HOSPITAL APPOINTMENTS

Attending Nephrologist, Division of Kidney Disease & Hypertension, Rhode Island Hospital, Providence, RI, 2008-present

Attending Nephrologist, The Miriam Hospital, Providence, RI, 2008-present

Consultant, Veterans Administration Medical Center, Providence, RI, 2008-present

Attending Nephrologist, Kent Hospital, Warwick RI, 2009-present

Director, home hemodialysis program, Dialysis Center of Rhode Island Hospital, 2011-2015

Attending Nephrologist, Charlton Hospital, Fall River, MA, 2015-2017

Affiliated Physician, Charlton Hospital, Fall River, MA, 2017-2019

Attending Nephrologist, St. Anne's Hospital, Fall River, MA, 2015-2018

Associate Medical Director, Transplant Clinic, Rhode Island Hospital, RI, 2015-present

Medical Director, Inpatient Dialysis Unit, Rhode Island Hospital, RI, 2016-present

Consultant, Women and Infants Hospital of Rhode Island, 2016-present

## NATIONAL APPOINTMENTS

American Society of Nephrology Workforce Committee 2011-2015

Subcommittee chair, web-based initiatives and public awareness, 2011-2012

Program leader, Kidney Mentoring Awareness Program for Students 2012-2015

Mentor, ASN Kidney Week, Philadelphia, PA November 2014

Mentor, ASN Kidney Week, San Diego, CA November 2015

Mentor, ASN Kidney Week, Chicago, IL November 2016

Mentor, ASN Kidney Stars Program, Alpert Medical School, Brown University 2012-2016,  
2018-2019

Mentor, ASN Kidney Week, San Diego, CA, November 2018

ASN Career Advancement Committee January-December 2020

Organ Procurement and Transplantation Network Ethics Committee July 2020 – present

United Network for Organ Sharing Ethics Committee July 2020 - present

OTHER APPOINTMENTS (NON-MEDICAL)

The Gainesville Sun, Reporter, Gainesville, Florida, 1982-1984

The New York Times, News Clerk and Summary Writer, New York, New York, 1985-1988

The Associated Press, Newsman, New York, New York, 1988-1989 and Newark, New Jersey,  
1989-1990

AP-Dow Jones News Services, Copyreader, New York, New York, 1990-1992

Dow Jones Capital Markets Report, Correspondent, Frankfurt, Germany, 1992-1994

AP-Dow Jones News Service, Bureau Chief, Prague, Czech Republic, 1994-1996

Dow Jones Newswires, Copyreader, Jersey City, New Jersey, 1997-2000

AD HOC REVIEWER AND EDITORIAL BOARD

Brown Medicine, Alpert Medical School, editorial board, 2004-2014

Hemodialysis International, 2011

Clinical Journal of the American Society of Nephrology, 2012-2014

BioMed Central Nephrology, 2012-2013

European Journal of Nutrition, 2015-present

Journal of Diabetes and its Complications, 2016-2017

Scientific Reports, 2016

International Journal of Nephrology and Renovascular Disease, editorial board 2016-present, ad  
hoc reviewer 2017

Journal of the American Society of Nephrology, 2017, 2020

Journal of the American College of Cardiology 2017-present

Chronic Diseases and Translational Medicine 2017, 2020

Genetic Testing and Molecular Biomarkers, 2017  
Therapeutics and Clinical Risk Management, 2017  
Blood Purification, 2017  
Nutrition, Metabolism and Cardiovascular Diseases, 2017-present  
JACC: Cardiovascular Imaging, 2018  
JACC: Heart Failure, 2019-present  
JACCBTS: 2022  
Experimental and Molecular Pathology, 2019  
American Journal of Nephrology, 2019-present  
American Journal of Kidney Disease, 2020  
Structural Heart: The Journal of the Heart Team, 2020  
Cell Death and Disease, 2020-present  
Rhode Island Medical Journal, associate editor, 2022-present

#### HOSPITAL COMMITTEES

Medical Executive Committee, The Miriam Hospital, June 2012-May 2014  
University Medicine Foundation, Thought Leaders Committee, 2013-2014  
Ethics Committee, Rhode Island Hospital, May 2014-present  
Mortality and Peer Review Committee, Department of Medicine/Rhode Island and Miriam Hospitals, 2015-present  
Continuing Medical Education (CME) Committee, Rhode Island, The Miriam and Newport Hospitals, June 2017-present.  
Coffee Rounds, monthly faculty development talks, organizer, Rhode Island Hospital 2018-present  
Education Committee, Brown Physicians Inc., 2019-present  
Lifespan ad-hoc COVID19 ethics committee, 2020-2021

#### DIVISION COMMITTEES

Planning committee chair, Renal Division Grand Rounds, Department of Medicine/Alpert Medical School, 2009-present

Planning committee chair, introductory lecture series for renal fellows, Renal Division, Department of Medicine/Alpert Medical School, 2009-2020

Organizer and planner, Renal Division morbidity and mortality conference, Department of Medicine/Alpert Medical School, 2010-present

#### UNIVERSITY COMMITTEES

Admissions Committee, Alpert Medical School, Brown, 2003, 2011-present

Interviewer, Department of Medicine Internal Medicine residency program, Alpert Medical School/Lifespan Hospitals, 2009-present

Director, Med A renal rotation, Department of Medicine, Alpert Medical School/Lifespan Hospitals, 2013-present

#### MEMBERSHIP IN SOCIETIES

American Medical Association, 1999-present

Rhode Island Medical Society, 1999-present

American College of Physicians, 2006-present

American Society of Nephrology, 2006-present

National Kidney Foundation, 2008-present

American Society of Transplantation 2013-present

International Society of Nephrology, 2016-present

#### COMMUNITY/CHARITABLE ACTIVITIES

National Kidney Foundation KEEP 2010, 2017

National Kidney Foundation Kidney Health Risk Assessment 2011

#### ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Farrag YM, **Bayliss GP**, Singh AK. The case: an unknown toxin. *Kidney Int* 2008 May;73(10):1201-2.
2. Cohen RA, **Bayliss G**, Crispin JC, Kane-Wanger GF, Van Beek CA, Kyttaris VC, Avalos I, Yu CY, Tsokos GC, Stillman IE. T cells and *in situ* cryoglobulin deposition in the pathogenesis of lupus nephritis. *Clinical Immunology* 2008 July;128(1):1-7.
3. **Bayliss G**, Jacobs WC, Williams ME. Renal failure and abdominal pain as the presenting symptoms of a rare tumor of the aorta masquerading as a calcified plaque. *NDT Plus* October 2008;1:316-318.

4. Crispin JC, Oukka M, **Bayliss G**, Cohen RA, Van Beek CA, Stillman IE, Kyttaris VC, Juang YT, Tsokos GC. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. *J Immunol* 2008 December 15; 181(12):8761-6.
5. Weinrauch LA, **Bayliss G**, Gleason RE, Lee AT, D'Elia JA. Utilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefit. *Metabolism* 2009;58(4):488-491.
6. Weinrauch LA, **Bayliss G**, Gleason RE, Lee AT, D'Elia JA. A pilot study to assess utility of changes in elements of the diabetes impact management scale in evaluating diabetic patients for progressive nephropathy. *Metabolism* 2009;58(4):492-496.
7. **Bayliss G** and Danziger J. Nocturnal versus conventional hemodialysis: some current issues. *Nephrol Dial Transplant* 2009;24(12):3612-3617. Epub 2009 Sep 19.
8. **Bayliss G**. Dialysis and the poisoned patient. *Hemodial Int.* 2010;14 (2):158-167. Epub 2010 Mar 19.
9. D'Elia JA, **Bayliss G**, Roshan B, Maski M, Gleason RE, Weinrauch LA. Diabetic microvascular complications: possible targets for improved macrovascular outcomes. *Int J Nephrol Renovasc Dis.* 2011;4:1-15. Epub 2010.
10. Hasnain W, Stillman IE, **Bayliss G**. Minimal change renal disease and Graves' disease: a case report and literature review. *NDT Plus* 2011;4(2):96-98. Epub 2011 Jan 27
11. Said F, Griffith R, **Bayliss G**. An unusual presentation of hematuria. *Kidney Int* 2011;79(8):923.
12. Liu N, Guo J-K, Maoying P, Tolbert E, Ponnusamy M, Gong, R, **Bayliss G**, Dworkin L, Yan H, Zhuang S. Inhibition of renal fibrosis by pharmacologic blockade of epidermal growth factor. *J Am Soc Nephrol* 2012;23(5):854-867. Feb 23 [Epub ahead of print].
13. **Bayliss G**, Roshan B, Ventrapragada SV, Gleason RE, Weinrauch LA, D'Elia JA. The Impact of a Prior History of Cardiovascular Events on Outcomes in Patients on Renal Replacement Therapy. *Int J Cardiol* 2012;157:146-148. Epub 2012 Mar 26.
14. Liu N, He S, Tolbert E, Gong R, **Bayliss G**, Zhuang S. Suramin alleviates glomerular injury and inflammation in the remnant kidney. *PLoS One.* 2012;7(4):e36194. Epub 2012 Apr 27.
15. **Bayliss G**, Weinrauch LA, D'Elia JA. Pathophysiology of Obesity-Related Renal Dysfunction Contributes to Diabetic Nephropathy. *Curr Diab Rep.* 2012 May 26. [Epub ahead of print] DOI: 10.1007/s11892-012-0288-1
16. He S, Liu N, **Bayliss G**, Zhuang S. EGFR activity is required for renal tubular cell dedifferentiation and proliferation in a murine model of folic acid-induced acute kidney injury. *Am J Renal Physiol.* 2013;304(4):F356-66. Epub 2012 Dec 19
17. Liu N, He S, Ma L, Ponnusamy M, Tang J, Tolbert E, **Bayliss G**, Zhao TC, Yan H, Zhuang S. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal

- fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS One. 2013;8(1):e54001. doi: 10.1371/journal.pone.0054001. Epub 2013 Jan 16.
18. Tang J, Liu N, Tolbert E, Ponnusamy M, Ma L, Gong R, **Bayliss G**, Yan H, Zhuang S. Sustained Activation of EGFR Triggers Renal Fibrogenesis after Acute Kidney Injury. *Am J Pathol.* 2013;183:160-72. Epub May 15.
  19. Tang J, Yan Y, Zhao TC, **Bayliss G**, Yan H, Zhuang S. Class I histone deacetylase activity is required for proliferation of renal epithelial cells. *Am J Physiol Renal Physiol.* 2013.1;305(3):F244-54. May 22. [Epub ahead of print]
  20. **Bayliss GP**, Gohh RY, Morrissey PE, Rodrigues JR, Mandelbrot DA. Immunosuppression After Renal Allograft Failure: A Survey of US Practices. *Clin Transplant.* 2013;27:895-900. Epub 2013 Oct. 11
  21. **Bayliss G**, Weinrauch LA, Gleason RE, Lee AT, D'Elia JA. Do biologic markers predict cardiovascular endpoints in diabetic end stage renal disease? A prospective longitudinal study. *Clinical Kidney Journal.* 2013;6:599-603.
  22. **Bayliss G**. Initiation of dialysis: A mini review of a changing paradigm. *Cardiovasc Hematol Disord Drug Targets.* 2014;14(3):165-9. April 1. [Epub ahead of print].
  23. Tang J, Yan Y, Zhao TC, Gong R, **Bayliss G**, Yan H, Zhuang S. Class I HDAC activity is required for renal protection and regeneration after acute kidney injury. *Am J Physiol Renal Physiol.* 2014 Aug 1;307(3):F303-16. doi: 10.1152/ajprenal.00102.2014. Epub 2014 May 7.
  24. **Bayliss G**, Weinrauch L and D'Elia J. Resistant hypertension in diabetes. *Curr Diab Rep.* 2014;14(8):516. DOI 10.1007/s11892-014-0516-y 2014.
  25. Yan Y, Bai J, Zhou X, Tang J Jiang C, Tolbert E, **Bayliss G**, Gong R, Zhao TC, Zhuang S. P2X7 receptor inhibitor protects against ischemic acute kidney injury in mice. *Am J Physiol Cell Physiol.* 2015 Jan 14: ajpcell.00245.2014. doi: 10.1152/ajpcell.0245.2014. [Epub ahead of print]
  26. Ponnusamy M, Zhuang MA, Zhou X, Tolbert E, **Bayliss G**, Zhao TC and Zhuang S. Activation of SIRT1 Promotes Renal Fibroblast Activation and Aggravates Renal Fibrogenesis. *JPET.* 2015 May 28. DOI: 10.1124/jpet.115.224386. [Epub ahead of print]
  27. Patel N and **Bayliss GP**. Developments in extracorporeal therapy for the poisoned patient. *Adv Drug Deliv Rev.* 2015;90:3-11. doi: 10.1016/j.addr.2015.05.017. [Epub ahead of print] Review.
  28. Kassakian CT, Ajmal S, Gohh RY, Morrissey PE, **Bayliss GP**. Immunosuppression in the failing and failed kidney transplant: optimizing outcomes. *Nephrol Dial Transplant.* 2015;31:1261-1269. [Epub ahead of print] Review.
  29. Yan Y, Ma L, Zhou X, Ponnusamy M, Tang J, Zhuang MA, Tolbert E, **Bayliss G**, Bai J, Zhuang S. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis. *Kidney Int.* 2015 Oct 7. doi: 10.1038/ki.2015.293. [Epub ahead of print].



30. Zhou X, Zhang X, Ponnusamy M, Masucci MV, Tolbert E, Gong R, Zhao TC, Liu N, **Bayliss G**, Dworkin LD, Zhuang S. Enhancer of zeste homolog 2 inhibition attenuates renal fibrosis by maintaining Smad7 and phosphatase and tensin homolog expression. *J Am Soc Nephrol* 2015 Dec 23. Pii ASN.2015040457. [Epub ahead of print].
31. Merhi B, **Bayliss G**, Gohh RY. Role for Urinary biomarkers of acute rejection in the transplanted kidney. *World J Transplant.* 2015;5:251-260.
32. Weinrauch LA, **Bayliss G**, Segal AR, Liu J, Wisniewski E, D'Elia JA. Renal function alters antihypertensive regimens in type 2 diabetic patients. *J Clin Hypertens (Greenwich).* 2016 Mar 2. doi: 10.1111/jch.12776. [Epub ahead of print]
33. Weinrauch LA, **Bayliss G**, Segal AR, Liu J, Wisniewski E, D'Elia JA. Treating hypertension in diabetic patients with advanced chronic kidney disease: what should we have in mind? *J Clin Hypertens (Greenwich).* 2016 May 11. doi: 10.1111/jch.12839. [Epub ahead of print]
34. D'Elia JA, **Bayliss G**, Gleason R, Weinrauch LA. Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review. *Clin Kidney J.* 2016;5:705-712.
35. Zhong C, Zang X, Zhou X, Masucci MV, Tang J, Liu N, **Bayliss G**, Zhao TC, Zhuang S. Pharmacological inhibition of Src kinase protects against acute kidney injury in a murine model of renal ischemia/reperfusion. *Oncotarget.* 2017;8:31238-31253.
36. Li X, **Bayliss G**, Zhuang S. Cholesterol crystal embolism and chronic kidney disease. In *J Mol Sci.* 2017 May 24; 18(6). Pii: E1120. doi: 10.3390/ijms 18061 120. Review.
37. Merhi B, Patel N, **Bayliss G**, Henriksen KJ, Gohh R. Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab. In press. *Clin Kidney J.* 2017 sfx001. doi: 10.1093/ckj/sfx001
38. Weinrauch LA, Segal AR, **Bayliss G**, Liu J, Wisniewski E, D'Elia JA. Changes in treatment of hyperglycemia in a hypertensive type 2 diabetes population as renal function declines. *Clin Kidney J.* 2017. Doi 10.1093/ckj/sfx020.

39. D'Elia JA, Segal AR, **Bayliss GP**, Weinrauch LA. Sodium glucose co-transport-2 inhibition and acidosis in Type 2 diabetic patients: a review of FDA data and possible conclusions. *Int J Nephrol Renovasc Dis.* 2017 Jun 15;10:153-158. Doi: 10.2147/IJNRD.S135899
40. Yee C, Himmelwright RS, Klyce W, Sankla T, **Bayliss GP**. Putting the “no” in non nocere: surgery, anesthesia and a patient’s right to withdraw consent. *RI Med J.* 2017;100:38-40.
41. Henriksen KJ, Chang A and **Bayliss GP**. Transplant outcomes in two adults with Down Syndrome. *Kidney International Reports.* 2018 Mar 2;3(4):979-984.
42. Zhou X, Xiong C, Tolbert E, Zhao TC, **Bayliss G**, Zhuang S. Targeting histone methyltransferase enhancer of zeste homolog-2 inhibits renal epithelial mesenchymal transition and attenuates renal fibrosis. *FASEB J.* 2018 May 18:fj201800237R. doi: 10.1096/fj.201800237R. [Epub ahead of print]
43. Shaban E, **Bayliss G**, Malhotra D, Shemin D, Wang L, Gohh R, Dworkin L, Gong R. Targeting regulatory T cells for transplant tolerance: new insights and future perspectives. *Kidney Diseases.* 2018 July 31. DOI: 10.1159/000490703
44. Zhou X, Zang X, Guan Y, Tolbert E, Zhao TC, **Bayliss G**, Zhuang S. Targeting enhancer of zeste homolog 2 protects against acute kidney injury. *Cell Death Dis.* 2018. Oct. 19;9(11):1067. Doi: 10.1038/s41419-018-1012-0.
45. Kim SH, Baird GL, **Bayliss G**, Merhi B, Osband A, Gohh R, Morrissey PE. A single-center analysis of early readmissions after renal transplantation. *Clin Transplant.* 2019 Mar 12:e13520. Doi: 10.1111/ctr.13520. [Epub ahead of print]
46. Chen DQ, Cao G, Chen H, Argyropoulos CP, Yu H, Su W, Chen L, Samuels CD, Zhuang S, **Bayliss GP** et al. Identification of serum metabolites associating with chronic kidney disease progression and antifibrotic effect of 5-methoxytryptophan. *Nat Commun.* 2019;10:1476 doi: 10.1038/s41467-019-09329-0.

47. Xiong C, Guan Y, Zhou X, Liu L, Zhang W, Zhang Y, Massucci MV, **Bayliss G**, Zhao TC, Zhuang S. Selective Inhibition of class IIa histone deacetylases alleviates renal fibrosis. *FASEB J*. 2019;33:8249-8262. doi: 10.1096/fj.201801067RR. Epub 2019 Apr 5.
48. **Bayliss G**. TAVR in patients with end-stage renal disease and critical aortic stenosis: hard choices. *J Am Coll Cardiol*. 2019;73:2816-2818. doi: 10.1016/j.jacc.2019.04.007.
49. Liu F, **Bayliss G**, Zhuang S. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases. *Clin Sci (Lond)*. 2019;133:1309-1320. doi: 10.1042/CS20190249.
50. Liu L, Guan Y, Zhang Y, Zhang W, Zhou X, Xiong C, Tolbert E, Zhao TC, **Bayliss G**, Zhuang S. Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial and mesenchymal transition. *FASEB J*. 2019Nov;33(11):11941-11958. doi: 10.1096/fj.201801861R. Epub 2019 Aug 2. PMID: 31373855
51. **Bayliss GP**, Cobb J, Decker B, Hellman R, Vasavada N, Shadur C, Ilori T, Ibrahim T, Leight K, Hsiao L, Molitoris BA, Okusa MD, Parker MG. Kidney MAPS: a guide for engaging medical students in nephrology. *Clin Kidney J*. 2019;12:761–766. <https://doi.org/10.1093/ckj/sfz108>.
52. Zhang Y, Jou J, Tolbert E, Zhao TC, **Bayliss G**, Zhuang S. Identification of histone deacetylase 8 as a novel therapeutic target for renal fibrosis. *FASEB J*. 2020 Apr 12. doi: 10.1096/fj.201903254R. [Epub ahead of print]
53. Naeem S, Gohh R, **Bayliss G**, Cosgrove C, Farmakiotis D, Merhi B, Morrissey P, Osband A, Bailey J, Sweeney J, Rogers R. Successful recovery from COVID-19 in three renal transplant recipients who received convalescent plasma therapy. *Transplant Infectious Disease*. 2020 Aug 19:e13451. doi: 10.1111/tid.13451. Online ahead of print.

54. Mitchell K, Bomm A, Shea BS, Shemin D, **Bayliss G**. Inpatient dialysis planning during the COVID-19 pandemic: A single center experience and review of the literature. *Int J Nephrol Renovasc Dis.* 2020;13:253-259.
55. Zhang W, Guan Y, **Bayliss GP**, Zhuang S. Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury. *Am J Physiol Renal Physiol.* 2020 Oct. 5. doi 10.1152/ajprenal.00405.2020. Online ahead of print.
56. Yu C, Xiong C, Tang J, Hou X, Liu N, **Bayliss G**, Zhuang S Histone demethylase JMJD3 protects against renal fibrosis by suppression TGF $\beta$  and Notch signaling and preserving PTEN expression. *Theranostics.* 2021. 1;11:2706-2721.
57. Hardesty A, Pandita A, Vieira K, Rogers R, Merhi B, Osband AJ, Aridi J, Shi Y, **Bayliss G**, Cosgrove C, Gohh R, Morrissey O, Beckwith CG, Farmakiotis D. Coronavirus Disease 2019 in kidney transplant recipients: Single-center experience and case-control study. *Transplant Proc.* 2021 Jan 13:S0041-1345(21)00003-8. doi: 10.1016/j.transproceed.2021.01.002. Online ahead of print.
58. Sheng L, **Bayliss G**, Zhuang S. Epidermal growth factor receptor: a potential target for diabetic kidney disease. *Front Pharmacol.* 2021. Jan 26;11:598910. doi: 10.3389/fphar.2020.598910. eCollection 2020.
59. **Bayliss G**. Frailty and kidney transplantation. *RI Med J.* *RI Med J* (2013). 2021 Feb 1;104(1):15-19.
60. Huang J, **Bayliss G**, Zhuang S. Porcine models of acute kidney injury. *Am J Physiol Renal Physiol.* 2021 Apr 26. doi: 10.1152/ajprenal.00022.2021. Online ahead of print.
61. Haeuser L, Marchese M, Cone, EB, Noldus J, **Bayliss G**, Kilbridge KL, Trinh QD. Nephrotoxicity in immune checkpoint inhibitors: a pharmacovigilance study. *Nephrol Dial Transplant.* 2021 May 24:gfab187. doi: 10.1093/ndt/gfab187. Online ahead of print.

62. Murphy M, Ding A, Berk J, Rich J, **Bayliss G**. Kidney disease among people who are incarcerated. *Clin J Am Soc Nephrol*. 2021 Jun 16;CJN.01910221. doi: 10.2215/CJN.01910221. Online ahead of print.
63. Liu L, Liu F, Guan Y, Zou J, Zhang C, Xiong C, Zhao TC, **Bayliss G**, Li X, Zhuang S. Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis. *FASEB J*. 2021 Jul;35(7):e21715. doi: 10.1096/fj.202000554RRR.
64. Shao M, Ye C, **Bayliss G**, Zhuang S. New insights into the effect of individual Chinese Herbal Medicines on Chronic Kidney Disease. *Front Pharmacol*. 2021. Nov. 4;12:774414. doi: 10.3389/fphar.2021.774414. eCollection 2021.
65. Shi Y, Lerner AH, Rogers R, Viera K, Merhi B, Osband AJ, **Bayliss G**, Gohh R, Morrissey P, Farmakiotis D. Low-dose valganciclovir prophylaxis is safe and cost-saving in CMV seropositive kidney transplant recipients. *Prog Transplant*. 2021 Dec;31(4):368-376. doi: 10.1177/15269248211046037.
66. Kulkarni S, Flescher A, Ahmad M, **Bayliss G**, Bearl D, Biondi L, Davis E, George R, Gordon E, Lyons T, Wightman A, Ladin K. Ethical analysis examining the prioritization of living donor transplantation in times of healthcare rationing. *J Med Ethics*. 2022 Jan 4;medethics-2021-107574. doi: 10.1136/medethics-2021-107574. Online ahead of print.
67. Toffaletti JG, Burke CO, **Bayliss G**, Lynch M. Utilizing longitudinal within-individual changes of serum creatinine, cystatin C and/or eGFR to optimize clinical sensitivity and eliminate race and gender corrections. *J Appl Lab Med*. 2022 Feb 9:jfac001. doi: 10.1093/jalm/jfac001. Online ahead of print.
68. Selvaraj V, Lal A, Finn A, Tanzer JR, Baig M, Jindal A, Dapaah-Afriye K, **Bayliss G**. Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease. *World J Crit Care Med*. 2022;11:48-57.

69. Yu, C, Li T, Li J, Cui B, Liu B, **Bayliss G**, Zhuang A. Inhibition of polycomb repressive complex 2 by EED protects against cisplatin-induced acute kidney injury. *Journal of Cellular and Molecular Medicine*, 2022 June 23. doi.org/10.1111/jcmm.17447.
70. **Bayliss G**. Practical ethic concerns in allocation of pig kidney to humans. *Clin Kidney J*. 2022 May 5;15(12):2161-2168. doi: 10.1093/ckj/sfac125. eCollection 2022 Dec.
71. **Bayliss G**. Mitochondrial DNA in uremia and new targets to treat myocardial hypertrophy in the cardiorenal syndrome. *JACC Basic Transl Sci*. 2022 Aug 22;7(8):841-843. doi: 10.1016/j.jacbts.2022.06.005. eCollection 2022 Aug.
72. D'Elia JA, **Bayliss GP**, Weinrauch LA. The diabetic cardiorenal nexus. *Int J Mol Sci*. 2022 Jul 1;23:7351. doi: 10.3390/ijms23137351.
73. Zhang C, Guan Y, Zou J, Yang X, **Bayliss G**, Zhuang S. Histone methyltransferase MLL1 drives renal tubular cell apoptosis by p53-dependent repression of E-cadherin during cisplatin-induced acute kidney injury. *Cell Death Dis*. 2022 Sep 6;13(9):770. doi: 10.1038/s41419-022-05104-0.
74. Warsame F, Chu NM, Mathur A, Crews DC, **Bayliss G**, Segev DL, McAdams-DeMarco MA. Sleep duration and cognitive function among older adults with chronic kidney disease – results from National Health and Nutrition Examination Survey (2011-2014). *Nephrol Dial Transplant*. 2022 Dec 19:gfac235. doi: 10.1093/ndt/gfac235. Online ahead of print.
75. Zou J, Yu C, Zhang C, Guan Y, Zhnag Y, Tolbert E, Zhang Q, Zhao T, **Bayliss G**, Li X, Ye Z, Zhuang S. Inhibition of MLL1-menin interaction attenuates renal fibrosis in obstructive nephropathy. *FASEB J*. 2023 Jan;37(1):e22712. doi: 10.1096/fj.202100634RRR.
76. Hammond R, Friedman JH, Korr KS, **Bayliss G**, Korr M, Binder W. Perspectives on the art of scientific and medical writing. *RI Med J (2013)*. 2023;106:65-68.

77. Yu J, Yu C, **Bayliss G**, Zhuang S. Protein arginine methyltransferase in renal development, injury, repair and fibrosis. *Front Pharmacol*. 2023 Feb 3;14:1123415. doi: 10.3389/fphar.2023.1123415. eCollection 2023.

#### OTHER NON-PEER REVIEWED PUBLICATIONS

1. **Bayliss G**. The Tsarist and Soviet Conquests of Kazakhstan. Senior Honors Thesis, Harvard University, 1982
2. **Bayliss G**. Sobriety from Above in the Soviet Union and the 1985 Anti-Alcohol Campaign. Certificate Essay, Harriman Institute for the Advanced Study of The Soviet Union, Columbia University, 1991

#### BOOKS AND BOOK CHAPTERS

1. O'Bell JW, **Bayliss GP**, Dworkin LD. Renal artery thrombosis, thromboembolism, aneurysms, atheroembolic and renal vein thrombosis. In *Schrier's Disease of the Kidney*, 9<sup>th</sup> Edition. Oct. 2012.

#### CORPORATE AUTHORSHIP OR MULTICENTER TRIALS

1. Rhode Island Hospital Principal Investigator, "Symptoms and Length of Stay after Sodium Correction in Inpatient Adults: Tolvaptan versus fluid restriction."
2. Rhode Island Hospital Principal Investigator, "SONAR: Study Of Diabetic Nephropathy with Atrasentan A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy."
3. Rhode Island Hospital Principal Investigator, "A Phase 2a Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease."

#### ABSTRACTS AND POSTER PRESENTATIONS

1. **Bayliss G** and Gopalakrishnan P. A confused alcoholic with renal failure with low platelets. *Am Coll Physic*, Rhode Island Chapter, 2004.
2. **Bayliss G** and Donat W. Aortic Dissection in a Hypertensive Patient Withdrawing from Cocaine. *Am Coll Physic*, Rhode Island Chapter, 2005.
3. **Bayliss G**, Reinert S, McKendall G, Shemin D. Relationship Between Volume of IV Contrast Dye and Contrast Nephropathy in Patients in CKD Undergoing Coronary Angiography. *J Am Soc Nephrol* 16:2006 (abs).
4. **Bayliss G**, Weinrauch L, Gleason R, Lee A, D'Elia J. Utility of Changes in Elements of the Diabetes Impact Management Scale in Evaluating Diabetes Patients for Progressive Nephropathy. *J Am Soc Nephrol* 18:950A, 2007 (pub).
5. Sim MR, **Bayliss G**, Wolf J, Davis R, Cohen RA. Serum Magnesium Concentration after Magnesium Citrate (Mg Cit) Bowel Preparation. *J Am Soc Neph* 19:938A, 2008 (pub).

6. **Bayliss G**, Pavlakis M, Goldfarb A, Sylvaria D, Monaco A, Mandelbrot D. Comparison of Outcomes in Renal Transplant Patients Whose Immunosuppression is Stopped Versus Continued. *J Am Soc Neph* 19:685A, 2008 (abs) .
7. Li J and **Bayliss G**. Mixed Cryoglobulinemia. *Am Coll Physic*, Rhode Island Chapter, 2009.
8. Ravindran L and **Bayliss G**. Native valve endocarditis caused by *Staphylococcus lugdunensis*. *Am Coll Physic*, Rhode Island Chapter, 2010.
9. Trowbridge P and **Bayliss G**. Renal Manifestations of non-renal sarcoid. *Am Coll Physic*, Rhode Island Chapter, 2011.
10. Spence L, Gentillesco B, **Bayliss G**. An unusual case of acute kidney injury. *Am Coll Physic*, Rhode Island, 2011.
11. Kassakian CT, **Bayliss GP**, Gentillesco B. Leave no stone unturned. *Am Coll Physic*, Rhode Island Chapter, 2011.
12. Ventrapragada SV, **Bayliss GP**, Roshan B, Gleason RE, Weinrauch LA, D'Elia JA. With Increased Inflammation, Fibrinolysis May Counterbalance Platelet Hyperactivity in Diabetic Hemo and Peritoneal Dialysis Patients. *J Am Soc Nephrol* 2011;22;907A (Pub283).
13. Roshan B, **Bayliss GP**, Ventrapragada SV, Gleason RE, Weinrauch LA, D'Elia JA. Usefulness of Biomarkers of Inflammation in Predicting Subsequent Cardiovascular Events in Diabetic Patients on Renal Replacement Therapy. *J Am Soc Nephrol* 2011;22;923A (Pub340).
14. **Bayliss GP**, Roshan B, Ventrapragada SV, Gleason RE, Weinrauch LA, D'Elia JA The Impact of a Prior History of Cardiovascular Events on Outcomes in Patients on Renal Replacement Therapy. *J Am Soc Nephrol* 2011;22;924A (Pub343).
15. **Bayliss GP**, Gohh RY, Morrissey PE, Rodrigue JR, Mandelbrot DA. A survey of US transplant center practices on immunosuppression after allograft fails. *J Am Soc Nephrol* 2012;23: 855A (PO0934).
16. Kassakian CT and **Bayliss GP**. Incidence of Infection in Patients Continued on Immunosuppression after Allograft Failure. *J Am Soc Nephrol* 2012;23:1077A (Pub 830).
17. Reznik T and **Bayliss G**. Weight gain and acute kidney injury in a 48-year-old HIV positive man. Senior research poster, Rhode Island Hospital, Providence, RI, June 2013.
18. Updike JA, Schleinitz MD, **Bayliss GP**. Chronic Kidney Disease in Primary Care: Assessing the role for subspecialty co-management. American Society of Nephrology 46<sup>st</sup> Annual Meeting and Scientific Exposition. Atlanta, GA. Nov. 7, 2013. (PO331).
19. Ajmal S, **Bayliss GP**, Machan JT, Kassakian CT, Morrissey PA. Impact of Transplant Nephrectomy on HLA-Sensitization and Re-Transplantation. American Society of Nephrology 46<sup>st</sup> Annual Meeting and Scientific Exposition. Atlanta, GA. Nov. 8, 2013. (PO1025).



20. Kassakian CT, Henriksen K, **Bayliss GP**. Minimization: AIDS Defining Illness Complicating Treatment of Minimal Change Disease American Society of Nephrology 46<sup>st</sup> Annual Meeting and Scientific Exposition. Atlanta, GA. Nov. 9, 2013. (PO661).
21. Shaban EM, **Bayliss GP**, Mermel L. Do Patients on Chronic Hemodialysis Have a Suppressed Fever Response to *S. aureus* Bacteremia? J Am Soc Nephrol 2013 Abstract supplement (PUB196).
22. DeWolfe D and **Bayliss G**. An Updated Assessment of CKD Management in the Primary Care Setting. J Am Soc Nephrol 2014 Abstract supplement (PUB230).
23. Kassakian CT and **Bayliss GP**. Infection and immunosuppression following renal transplant failure. American Society of Nephrology 47<sup>th</sup> Annual Meeting and Scientific Exposition. Philadelphia, PA, Nov. 13, 2014 (TH-PO1108).
24. Beckman R, Skierkowski D, Gohh R and **Bayliss G**. Current Practices in Screening and Management of Prostate Cancer in Renal Transplant Recipients: A Survey of US Transplant Centers. American Society of Nephrology 47<sup>th</sup> Annual Meeting and Scientific Exposition. Philadelphia, PA, Nov. 13, 2014 (TH-PO1116).
25. Zhou X, Ponnusamy M, Tolbert E, **Bayliss G**, Zhuang S. Histone methyltransferase EZH2: A novel therapeutic target for renal fibrosis. J Am Soc Nephrol 2015 Abstract supplement (SA-PO459).
26. Yan Y, Ponnusamy M, Tolbert E, **Bayliss G**, Zhuang S. Src kinase is a potential therapeutic target in renal fibrosis. J Am Soc Nephrol 2015 Abstract supplement (PUB392).
27. Wilber JJ, Dugdale C and Bayliss G. Disseminated cryptococcal infection in a 24-year-old man with focal segmental glomerular sclerosis. J Am Soc Nephrol 2015 Abstract supplement (PUB414).
28. Bien J and **Bayliss G**. A rare case of Guillain-Barré syndrome associated with Cytomegalovirus infection in a renal transplant patient. J Am Soc Nephrol 2015 Abstract supplement (PUB665).
29. Henriksen KJ and **Bayliss GP**. Transplant outcomes in two adults with Down Syndrome. J Am Soc Nephrol 2016 Abstract supplement (PUB794).
30. Qadeer F, **Bayliss GP**, Sharif S. Primary tubulointerstitial lupus nephritis complicated by diffuse alveolar hemorrhage. Accepted for presentation at ASN Kidney Week 2017
31. Viswanath M, Bayliss GP, Merhi BO. Recurrent proliferative glomerulonephritis with monoclonal IgG deposits in a renal allograft – still a dilemma. J Am Soc Nephrol 2018 abstract supplement PUB624
32. Liu L, Liu F, Xiong C, Tolbert E, **Bayliss GP**, Zhuang S. Lysine methyltransferase SMYD2 inhibition ameliorates renal fibrosis through suppression of renal fibroblast to myofibroblast transition. J Am Soc Nephrol 2019 abstract supplement TH-P0502
33. Zhang Y, Tolbert E, **Bayliss GP**, Zhuang S. Selective inhibition of histone deacetylase 8 suppresses renal fibroblast activation and mitigates renal fibrosis. J Am Soc Nephrol 2019 abstract supplement TH-P0503

## LOCAL INVITED PRESENTATIONS

1. Relationship between volume of IV contrast dye and contrast nephropathy in patients in CKD Undergoing Coronary Angiography. Senior Resident Research Day, Rhode Island Hospital/Brown Medical School, Providence, RI, May 11, 2006
2. Current issues in nocturnal dialysis. Renal Grand Rounds, Division of Kidney Diseases and Hypertension, Rhode Island Hospital, Providence, RI, Nov. 20, 2007
3. Update on lupus nephritis. Rheumatology Grand Rounds, Roger Williams Medical Center, Providence, RI, May 8, 2009
4. Prevention of Kidney Disease. Nephrology Update – Clinical Pearls in Nephrology. Grand Rounds, Department of Medicine, Rhode Island Hospital, Providence, RI, Nov. 24, 2009
5. Dialysis in the poisoned patient. Emergency Medicine Toxicology Conference, Rhode Island Hospital, Dec. 11, 2009
6. Dialysis in the poisoned patient. Renal Grand Rounds, Division of Kidney Diseases and Hypertension, Rhode Island Hospital, Providence, RI, April 16, 2010
7. HIV and chronic kidney disease. Division of Infectious Diseases Grand Rounds, The Miriam Hospital, Providence, RI, July 29, 2010
8. Acute Kidney Injury Criteria. Nephrology Update. Grand Rounds, Department of Medicine, Rhode Island Hospital, Providence, RI, Nov. 23, 2010
9. Update on lupus nephritis. Rheumatology Grand Rounds, Roger Williams Medical Center, Providence, RI, March 4, 2011
10. Chronic Kidney Disease Update. Nephrology Update. Grand Rounds, Department of Medicine, Rhode Island Hospital, Providence, RI, Nov. 1, 2011
11. Can we develop clinical guidelines for initiating dialysis? Renal Grand Rounds, Division of Kidney Diseases and Hypertension, Rhode Island Hospital, Providence, RI, Jan. 6, 2012
12. The effect of loss of nephron mass on progression of chronic kidney disease. Urology Grand Rounds, Rhode Island Hospital, Providence, RI, Oct. 24, 2012
13. Nephrology in critical care nursing. Critical care nursing training, Rhode Island Hospital, Providence, RI, Oct. 25, 2012
14. Nephrology in critical care nursing. Critical care nursing training, Rhode Island Hospital, Providence, RI, May 30, 2013
15. Is there a therapeutic role for medical marijuana in patients with advanced chronic kidney disease? Renal Grand Rounds, Division of Kidney Diseases and Hypertension, Rhode Island Hospital, Providence, RI, May 1, 2015
16. Update in living donor kidney transplantation. Grand Rounds, Department of Medicine, Rhode Island Hospital, Providence, RI, June 27, 2017

17. Kidney Transplantation in the Age of Medical Marijuana. Renal Grand Rounds, Division of Kidney Diseases and Hypertension, Rhode Island Hospital, Providence, RI, March 16, 2018
18. Lithium and the kidney. Renal Grand Rounds, Division of Kidney Diseases and Hypertension, Rhode Island Hospital, Providence, RI, Dec. 14, 2018
19. Ceremony of gratitude to anatomic donors, Alpert Medical School, Providence, RI, May 3, 2019
20. Nephrology for critical care nursing. University of Rhode Island Critical Care Nurse Practitioner Course, Providence, RI, Nov. 18, 2019
21. The ethics of living kidney donation. Rhode Island Hospital Ethics Committee, Providence, RI, Feb 11, 2020
22. A transplant patient who crossed state lines without insurance: a case of what would you do. Transplant Grand Rounds, Division of Organ Transplantation, Rhode Island Hospital, Providence, RI, March 20, 2020
23. CKD and the environment. Renal Grand Rounds, Division of Kidney Diseases and Hypertension, Rhode Island Hospital, Providence, RI, March 27, 2020
24. Nephrology for critical care nursing. University of Rhode Island Critical Care Nurse Practitioner Course, Providence, RI, Sept. 28, 2020
25. Mechanisms of renal injury: update on research into fibrosis and possible therapeutic intervention. Renal Grand Rounds, Division of Kidney Diseases and Hypertension, Rhode Island Hospital, Providence, RI, Oct. 30, 2020
26. Outpatient nephrology. University of Rhode Island College of Nursing Nurse Practitioner Course, Providence, RI, Nov. 29, 2021.
27. Social determinants of chronic kidney disease. Renal Grand Rounds, Division of Kidney Diseases and Hypertension, Rhode Island Hospital, Providence, RI, May 27, 2022.

#### NATIONAL INVITED PRESENTATIONS

1. Relationship between volume of IV contrast dye and contrast nephropathy in patients in CKD undergoing coronary angiography. American Society of Nephrology 39<sup>th</sup> Annual Meeting and Scientific Exposition. San Diego, CA. Nov. 15, 2006
2. TDF-SUN: Renal effects of tenofovir in the SUN Study. SUN Study Investigators Meeting, Providence, RI, June 4, 2012
3. A survey of US transplant center practices on immunosuppression after allograft fails. American Transplant Congress, Seattle, WA, May 21, 2013.

4. Immunosuppression and the failing/failed renal transplant: Optimizing outcomes. Renal Division Grand Rounds, University of North Carolina School of Medicine, Chapel Hill, NC, Feb. 26, 2014
5. Kidney MAPS: Blazing New Trails Toward An Expanded Workforce. American Society of Nephrology Workforce Committee Retreat, Washington, DC, March 12, 2014
6. Lithium and the kidney. Annual meeting of the Academy of Consultation-Liaison Psychiatry, Orlando, FL, Nov. 17, 2018

INTERNATIONAL INVITED PRESENTATIONS

1. SGLT2 inhibitors: from diabetic drug to CKD drug. Renal Division Grand Rounds, Department of Nephrology, Hainan General Hospital, Haikou, China. Invited web presentation. May 26, 2021

UNIVERSITY TEACHING ROLES (Alpert Medical School)

Course Title	Role	# Students Per Session	Hours Per Session	Sessions Per Year	Academic Years
Biol 3664 Renal Pathophysiology	Small Group Leader	7-9	1	8	2008-2015, 2017-present
IM 301 Medicine Clerkship	Inpatient Preceptor	3-4 3-4	1 2	8-16 4	2008-2014 2015-present
IM 301 Medicine Clerkship	Outpatient Preceptor	1	3	30	2008-present
IM 301 Medicine Clerkship	Case discussion	10	1	3	2015-present

HOSPITAL TEACHING ROLES (Rhode Island and Miriam Hospitals)

Course Title	Role	#Students (S) #Residents (R) # Fellows (F)	Hours Per Session	Sessions Per Year	Academic Years
Outpatient Clinic	Attending Physician	1 R	3-4	30	2010-2018
		1F	3-4	30	2012-2016
		1S	3-4	30	2016-present

Renal Consult Service	Attending Physician	1 S 1-2 R 1 F	6-8	2-4 weeks	2008- present
Med A Dialysis Service	Attending Physician	1 S 2 R 1F	4-6	2-4 weeks	2008-present
Med A Transplant Service	Attending Physician	1 S 2 R 1F	4-6	14-16 weeks	2013- present
Resident Noon Conference (topics listed below)	Lecturer	4-6 S 6-8 R	1	3-4	2008-present
Renal Fellow Noon Conference (topics listed below)	Lecturer	3-4 F	1	2-3	2008-present
DGIM Resident conference	Lecturer	5 R	1-2	2	2015-present
Morbidity&Mortality Conference (topics listed below)	Lecturer, Discussant	8-10 S 10-15 R	1	2-3	2008-present
URI College of Nursing NP Renal Elective	Attending Physician	1 S	3-4	14	2012-present
Dementia PBL	Discussant	8 S	1.5	4	2015-2017
Hypertension PBL	Discussant	8 S	1.5	4	2017-present

#### HOUSE STAFF CONFERENCES

1. Renal Transplant Review. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Nov. 10, 2008

2. Volume Disorders. House Staff Noon Conference, Providence VA Medical Center, Providence, RI, March 2, 2009
3. Glomerulonephritis. House Staff Noon Conference, The Miriam Hospital, Providence, RI, April 6, 2009
4. Acute Kidney Injury. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Sept. 11, 2009
5. Chronic Kidney Disease. House Staff Noon Conference, The Miriam Hospital, Providence, RI Oct. 27, 2009
6. Glomerulonephritis. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Jan. 25, 2010
7. Secondary Hypertension. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Feb. 3, 2010
8. Disorders of Water Handling. House Staff Noon Conference, The Miriam Hospital, Providence, RI, May 7, 2010
9. Volume disorders and hypertension. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Oct. 13, 2010
10. Glomerulonephritis. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Nov. 10, 2010
11. Secondary Hypertension. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Dec. 8, 2010
12. Chronic Renal Failure. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Oct. 31, 2011
13. Volume Disorders. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Nov. 21, 2011
14. Kidney Stones. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Feb. 1, 2012
15. Sodium Disorders. House Staff Noon Conference, The Miriam Hospital, Providence, RI, May 2, 2012
16. Dialysis. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Aug. 22, 2012
17. Chronic Kidney Disease. House Staff Noon Conference, Rhode Island Hospital, Nov. 28, 2012
18. Nephrolithiasis, House Staff Noon Conference, The Miriam Hospital, Providence, RI, April 22, 2013
19. Disorders of Water Handling. House Staff Noon Conference, The Miriam Hospital, Providence, RI, Sept. 9, 2013

20. Secondary and Resistant Hypertension. House Staff Noon Conference, The Miriam Hospital, Providence, RI, March 3, 2014
21. Renal division research presentation. House Staff Noon Conference, Rhode Island Hospital, Providence, RI, Oct. 1, 2014
22. Secondary and Resistant Hypertension. House Staff Noon Conference, The Miriam Hospital, May 18, 2015
23. Renal Division Research Update. House Staff Noon Conference, Rhode Island Hospital, Jan. 6, 2016
24. Acid Base Problems from the American Society of Nephrology. House Staff Noon Conference, The Miriam Hospital, Aug. 23, 2016
25. Outpatient Nephrology. Dept. of Medicine General Internal Medicine intern lecture, Rhode Island Hospital, 2016-present (annual recurrent talk).
26. Transplantation. House Staff Noon Conferences, Rhode Island, Miriam and Providence VA Hospitals, May 10, 20 and 23, 2016, respectively.
27. Tubular interstitial disease. House Staff Noon Conference, Rhode Island Hospital, Oct. 2, 2017
28. Transplant Complications. House Staff Noon Conference, Rhode Island Hospital, May 17, 2018
29. Disorders of potassium. House Staff Noon Conference, The Miriam Hospital, June 22, 2018
30. Transplant Complications. House Staff Noon Conference. Rhode Island Hospital, Nov. 18, 2019
31. Acute Kidney Injury. House Staff Noon Conference. Rhode Island Hospital, Sept. 9, 2021
32. Nephrology Potpourri. House Staff Noon Conference. Rhode Island Hospital, Jan. 20, 2022
33. Outpatient nephrology. GIM intern conference. Rhode Island Hospital, Feb. 9, 2022
34. Acute Kidney Injury. House Staff Noon Conference. Rhode Island Hospital, July 12, 2022

#### RENAL AND CRITICAL CARE FELLOWS CONFERENCES

1. Volume disorders and hypertension. Renal Fellow Noon Conference, Rhode Island Hospital, Aug. 27, 2009

2. Acute Kidney Injury. Critical Care Fellows Conference, The Miriam Hospital, Providence, RI, Jan. 19, 2010
3. Volume disorders and hypertension. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Sept. 1, 2010
4. Dialysis in the Poisoned Patient. Critical Care Fellows Conference, The Miriam Hospital, Providence, RI, Nov. 18, 2010
5. Sodium, Volume and Hypertension. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, July 7, 2011
6. Renal Replacement Therapy in the ICU. Critical Care Fellows Lecture, The Miriam Hospital, Providence, RI, July 29, 2011
7. Sodium, Volume and Hypertension. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, July 12, 2012
8. Home Hemodialysis: A Brief Overview. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Aug. 30, 2013
9. Clinical Trials Monthly Meeting. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Jan. 31. 2014
10. Renal Biopsies. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Oct. 2, 2014
11. Home Hemodialysis. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Oct. 3, 2014
12. Tubulointerstitial Disorders. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, March 16, 2015
13. Immunosuppression and the failing/failed renal transplant: Optimizing outcomes. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Aug. 28, 2015.
14. Home Hemodialysis: A Brief Overview. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Sept. 25, 2015.
15. Immunosuppression and the failing/failed renal transplant: Optimizing outcomes. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Aug. 18, 2016.
16. Home Hemodialysis: A Brief Overview. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Oct 6, 2016.
17. Chronic Kidney Disease. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Oct. 6, 2017.
18. Renal Transplantation. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Aug. 23, 2018.
19. Tubulointerstitial Disease. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Aug. 31, 2018



20. Chronic Kidney Disease. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Oct. 5, 2018.
21. Chronic Kidney Disease. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Aug. 22, 2019.
22. Tubulointerstitial Disease. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Sept. 5, 2019.
23. Transplant complications. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, July 23, 2020.
24. Transplant complications. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, July 8, 2021.
25. Tubulointerstitial Disease. Renal Fellows Noon Conference, Rhode Island Hospital, Providence, RI, Sept. 17, 2021.

#### MORBIDITY AND MORTALITY CONFERENCES

1. Acute aspirin toxicity in 51-year-old woman. Morbidity and Mortality Conference, The Miriam Hospital, Providence, RI, Oct. 1, 2008
2. A 27-year-old man who refuses initiation of dialysis. Morbidity and Mortality Conference, The Miriam Hospital, Providence, RI, March 25, 2009
3. A 48-year-old man with ESRD presents with fevers and chills. Morbidity and Mortality Conference, The Miriam Hospital, Providence, RI, Dec. 2, 2009
4. A 74-year-old man with renal artery stenosis. Morbidity and Mortality Conference, The Miriam Hospital, Providence, RI, Feb. 2, 2010
5. Images in clinical medicine – myeloma plasma cell infiltration of renal interstitium. Morbidity and Mortality Conference, The Miriam Hospital, Providence, RI, Nov. 17, 2010
6. We Hardly Knew You. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, March 29, 2011
7. Images in clinical medicine – A 56-year-old woman with HCV, CLL and proteinuria. Morbidity and Mortality Conference, The Miriam Hospital, Providence, RI, May 18, 2011
8. Handoff dropped at the end of life. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, Aug. 30, 2011
9. Bleeding after renal biopsy in a patient with normal platelets and coagulation studies. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, Nov. 29, 2011
10. Dialyzing a patient in a persistent vegetative state. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, Oct. 30, 2012

11. An 87-year-old man on high-dose prednisone for vasculitis. Morbidity and Mortality Conference, The Miriam Hospital, Providence, RI, April 24, 2013
12. Death after a renal biopsy: A systems failure. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, May 7, 2013
13. Elevated liver enzymes in a chronic hemodialysis patient. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, Sept. 30, 2014
14. An 87-year-old woman admitted with altered mental status. Morbidity and Mortality Conference, The Miriam Hospital, Providence, RI, Feb. 25, 2015
15. A 56-year-old woman with elevated lithium levels. Morbidity and Mortality Conference, The Miriam Hospital, Providence, RI, Sept. 9, 2015.
16. Renal M&M: Lessons Learned. Renal Division case conference, Division of Kidney Diseases and Hypertension, Rhode Island Hospital, Providence, RI, May 31, 2016
17. Hyperkalemia practice update, Grand Rounds, Department of Medicine, Rhode Island Hospital July 26, 2016 (part of larger M&M conference "A 66-year-old woman with AV fistula malfunction.")
18. Infection versus rejection. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, Aug. 29, 2017
19. An 89-year-old man with CKD IV, severe AS and need for contrast study ahead of TVAR procedure, Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, Oct. 31, 2017
20. Renal M&M 2016-2017: Lessons learned and applied. Renal Division case conference, Division of Kidney Diseases and Hypertension, Rhode Island Hospital, Jan. 30, 2018
21. 55-year-old man with history of renal transplant, chronic pain and traumatic brain injury following a motorcycle accident, opioid and benzodiazepine dependence who presents with a witnessed seizure and behavioral changes. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, July 31, 2018
22. A 55-year-old man with a kidney transplant, pain, opioid dependence and multiple admissions for hyperkalemia. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, Jan. 29, 2019
23. Renal M&M 2018-2019 Year in Review: Lessons learned. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, July 30, 2019

24. Renal M&M Year in Review 2019-2020. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, March 30, 2021
25. Code Status: a study in four cases. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, June 28, 2021
26. A missed lab. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, Nov. 30, 2021
27. Poor outcomes in two patients on dialysis. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, March 29, 2022.
28. Renal M&M Year in Review 2021-2022. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, Nov. 29, 2022
29. Renal M&M Two recent transplant cases. Renal Division Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, March 14, 2023.

#### FACULTY DEVELOPMENT CONFERENCES

1. By the light of the silvery moon: resident moonlighting. Coffee Rounds, Department of Medicine Faculty Series, Rhode Island Hospital, Providence, RI, April 10, 2012
2. How can we help residents cope with grief and loss? Coffee Rounds, Department of Medicine Faculty Development Series, Rhode Island Hospital, Providence, RI, Jan. 14, 2014
3. If Ansel Adams were a nephrologist: Using your cell phone camera for urine photo microscopy as a teaching tool. Coffee Rounds, Department of Medicine Faculty Development Series, Rhode Island Hospital, Providence, RI, Sept. 9, 2014
4. Teaching lifelong learning to learners. Coffee Rounds, Department of Medicine Faculty Development Series, Rhode Island Hospital, Providence, RI, Dec. 8, 2015
5. Mentoring trainees on career choices. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, April 11, 2017
6. The value of involving trainees in ongoing morbidity and mortality reviews: Moving beyond learning from mistakes to analyzing them. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Feb. 13, 2018
7. What is faculty development? Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, March 20, 2018
8. Implicit bias and BRIM. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Sept. 18, 2018
9. Why we stay in academic medicine. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Oct. 16, 2018

10. Emotional intelligence. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Nov. 13, 2018
11. Supervision versus independence in resident training. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Jan. 8, 2019
12. Predatory Publishing and Academic Medicine. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Feb. 12, 2019
13. Methods for teaching medication reconciliation. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Mar. 12, 2019
14. Do we need to rethink the “feedback sandwich?” Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, April 9, 2019
15. The challenge of having multiple levels of learners on a team (medical student, intern, resident, fellow, attending). Can we turn it around to having multiple levels of teachers? Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, May 14, 2019
16. Discussing ways to increase Coffee Rounds attendance and ideas for topics for the coming academic year. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, June 11, 2019
17. Teaching Residents to Have Hard Conversations. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Sept. 10, 2019
18. Helping Residents Cope with Moral Distress. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Nov. 11, 2019
19. The role of teaching cost consciousness to residents as part of internal medicine training. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Dec. 12, 2019
20. Teaching interns to teach. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Jan. 14, 2020
21. Determinants of health in Rhode Island. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Feb. 11, 2020
22. Preparing residents to handle disaster. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, March 10, 2020
23. Staying on track professionally during the COVID-19 pandemic. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, January 12, 2021
24. Race in medicine. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Feb. 15, 2021.

25. Burnout in the pandemic. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, March 10, 2021
26. Effects of the COVID-19 pandemic on academic productivity and data on how this has disproportionately affected women in medicine. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, April 13, 2021
27. Challenges facing clinician educators as they seek promotion in academic medical centers. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, May 18, 2021
28. How to teach the need for attention and ability to prioritize to trainees. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Nov. 16, 2021
29. Coaching as a more involved form of feedback. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Dec. 14, 2021
30. Resident perception of feedback in the new competency based medical education. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Jan. 11, 2022
31. Promoting diversity in medical faculty. Coffee Rounds, Department of Medicine Faculty Development Series. Rhode Island Hospital, Providence, RI, Feb. 8, 2022